Paper41553253
Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study.
Malagelada C and 9 others. Neurogastroenterol Motil, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study. Papers, record 41553253. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41553253
- Disease
- intestinal pseudo-obstruction3 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study.
- PubMed
- Publication types
- Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Multicenter Study
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Intestinal Pseudo-Obstruction | Major topic |
| Serotonin 5-HT4 Receptor Agonists | Major topic |
| Humans | |
| Male | |
| Middle Aged | |
| Female | |
| Double-Blind Method | |
| Cross-Over Studies | |
| Adult | |
| Aged | |
| Treatment Outcome | |
| Proof of Concept Study | |
| Young Adult | |
| Aged, 80 and over | |
| Chronic Disease | |
| Adolescent | |
| Gastrointestinal Motility | |
| Benzamides | |
| Thiazoles |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Alfasigma S.p.A. | PubMed | |||
| United European Gastroenterology | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05724069 | Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). | Derived from the trial | Yes |
Source ClinicalTrials.gov
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29570554 | Paediatric Intestinal Pseudo-obstruction: Evidence and Consensus-based Recommendations From an ESPGHAN-Led Expert Group. | J Pediatr Gastroenterol Nutr | 2018 | https://conductscience.org/library/papers/29570554 | PubMed |
| 2 | 15084181 | Intestinal transplantation for chronic intestinal pseudo-obstruction in adult patients. | Am J Transplant | 2004 | https://conductscience.org/library/papers/15084181 | PubMed |
| 3 | 19367271 | Long-term outcome of chronic intestinal pseudo-obstruction adult patients requiring home parenteral nutrition. | Am J Gastroenterol | 2009 | https://conductscience.org/library/papers/19367271 | PubMed |
| 4 | 21039672 | Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. | Aliment Pharmacol Ther | 2010 | https://conductscience.org/library/papers/21039672 | PubMed |
| 5 | 41209870 | Hydrogen-Positive Small Intestinal Bacterial Overgrowth (SIBO) in Japanese Patients With Chronic Intestinal Pseudo-Obstruction (CIPO): A Cross-Sectional Study. | Cureus | 2025 | https://conductscience.org/library/papers/41209870 | PubMed |
| 6 | 38562545 | Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial. | Biosci Microbiota Food Health | 2024 | https://conductscience.org/library/papers/38562545 | PubMed |
| 7 | 22959244 | Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation. | Bioorg Med Chem Lett | 2012 | https://conductscience.org/library/papers/22959244 | PubMed |
| 8 | 36939480 | Pharmacological and nutritional therapy of children and adults with chronic intestinal pseudo-obstruction. | Expert Rev Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36939480 | PubMed |
| 9 | 34946150 | Chronic Intestinal Pseudo-Obstruction: Is There a Connection with Gut Microbiota? | Microorganisms | 2021 | https://conductscience.org/library/papers/34946150 | PubMed |
| 10 | 19308797 | Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility. | Scand J Gastroenterol | 2009 | https://conductscience.org/library/papers/19308797 | PubMed |
| 11 | 27683196 | Chronic intestinal pseudo-obstruction in children and adults: diagnosis and therapeutic options. | Neurogastroenterol Motil | 2017 | https://conductscience.org/library/papers/27683196 | PubMed |
| 12 | 22356640 | Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. | Aliment Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22356640 | PubMed |
| 13 | 3817584 | Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. | Gut | 1987 | https://conductscience.org/library/papers/3817584 | PubMed |
| 14 | 18408918 | The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. | Naunyn Schmiedebergs Arch Pharmacol | 2008 | https://conductscience.org/library/papers/18408918 | PubMed |
| 15 | 15880314 | Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. | Clin Gastroenterol Hepatol | 2005 | https://conductscience.org/library/papers/15880314 | PubMed |
| 16 | 41553253 | Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study. | Neurogastroenterol Motil | 2026 | https://conductscience.org/library/papers/41553253 | PubMed |
| 17 | 29180358 | Nonclinical Cardiovascular Studies of Prucalopride, a Highly Selective 5-Hydroxytryptamine 4 Receptor Agonist. | J Pharmacol Exp Ther | 2018 | https://conductscience.org/library/papers/29180358 | PubMed |
| 18 | 23797870 | Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. | Nat Rev Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/23797870 | PubMed |
| 19 | 2022163 | Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. | Dig Dis Sci | 1991 | https://conductscience.org/library/papers/2022163 | PubMed |
| 20 | 15932370 | Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. | Aliment Pharmacol Ther | 2005 | https://conductscience.org/library/papers/15932370 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41553253 | Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study. | Neurogastroenterol Motil | 2026 | https://conductscience.org/library/papers/41553253 |
Source PubMed
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| VELUSETRAG | CHEMBL2087337 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2087337 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41553253
GET https://conductscience.org/api/papers/v1/41553253/references?page=2